The earnings call highlighted strong growth in key areas like Cardiac Ablation Solutions and Diabetes, leading to an increased EPS guidance. However, some areas like MedSurg and Neuroscience experienced slower growth, and tariffs continue to present a financial challenge.

Company Guidance

In the recent first-quarter earnings call, Medtronic reported a consistent mid-single-digit revenue growth, aligning with their guidance, and an EPS that surpassed expectations. Key highlights included a high single-digit growth in their Cardiovascular segment, particularly in Cardiac Ablation Solutions, which saw nearly 50% growth. The Neuroscience segment grew by 3%, with notable expansion in Neurosurgery and Neuromodulation. MedSurg grew by 2%, while the Diabetes division reported an 8% growth, bolstered by international markets. Medtronic raised its full-year EPS guidance, reflecting a strong start to the fiscal year and anticipating accelerated growth driven by their robust product pipeline and strategic initiatives. The company also discussed the planned separation of the Diabetes business, expected to be EPS accretive, and the formation of new board committees focused on growth and operational excellence.

Cardiac Ablation Solutions Growth

CAS grew nearly 50% with low 70s growth in both the U.S. and Japan, driven by high demand for Pulsed Field Ablation systems.

Improvement in Diabetes Segment

Diabetes grew 8%, with 11% growth in international markets, driven by the success of the 780G system and Simplera Sync sensor.

Increased EPS Guidance

EPS came in ahead of guidance, leading to an increase in EPS guidance for the full year to a range of $5.60 to $5.66.

Neuroscience Growth

Neuroscience grew 3%, supported by high single-digit growth in both Neurosurgery and Neuromodulation.

Strong Performance in Cardiovascular

Cardiovascular grew 7%, led by strong growth in Cardiac Ablation Solutions and double-digit growth in cardiac surgery, ICDs, and Leadless Pacing.

Medtronic (MDT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MDT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2026 (Q2)	1.31 / -	1.26	―	―	―
Aug 19, 2025	2026 (Q1)	1.23 / 1.26	1.23	2.44% (+0.03)
May 21, 2025	2025 (Q4)	1.58 / 1.62	1.46	10.96% (+0.16)
Feb 18, 2025	2025 (Q3)	1.36 / 1.39	1.3	6.92% (+0.09)
Nov 19, 2024	2025 (Q2)	1.25 / 1.26	1.25	0.80% (+0.01)
Aug 20, 2024	2025 (Q1)	1.20 / 1.23	1.2	2.50% (+0.03)
May 23, 2024	2024 (Q4)	1.45 / 1.46	1.57	-7.01% (-0.11)
Feb 20, 2024	2024 (Q3)	1.26 / 1.30	1.3	0.00% (0.00)
Nov 21, 2023	2024 (Q2)	1.18 / 1.25	1.3	-3.85% (-0.05)
Aug 22, 2023	2024 (Q1)	1.11 / 1.20	1.13	6.19% (+0.07)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MDT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 19, 2025	$92.81	$89.90	-3.14%
May 21, 2025	$85.66	$83.71	-2.28%
Feb 18, 2025	$91.32	$84.69	-7.26%
Nov 19, 2024	$85.44	$82.92	-2.95%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.